Anchored in our Code of Ethics, Novartis Ethics, Risk and Compliance (ERC) Program sets clear principles and expectations for ethical conduct, guiding decision making and leadership behavior across the company, with a focus on effectiveness rather than targets. In addition, the program supports performance while meeting and exceeding regulatory and societal expectations on ethical behavior, anti corruption, human rights, and environmental responsibility.<\/p>\n
Measuring our progress<\/p>\n
Social impact and sustainability is integral to how Novartis creates value\u00a0\u2013\u00a0shaping how we innovate, how our medicines reach patients, and how we contribute to stronger health systems and a healthier planet.\u00a0<\/p>\n
Our new long-term targets focus on where we can have the greatest impact, reinforcing our commitment to go first and to maximize the value of our medicines. By measuring and publicly reporting our progress, we aim to drive accountability, accelerate delivery and help unlock better health outcomes for patients and communities around the world.\u00a0<\/p>\n
Stay up to date on Social Impact & Sustainability<\/p>\n
Make sure to keep up with our milestones and achievements as we go through the year by following our channels.<\/p>\n","protected":false},"excerpt":{"rendered":"Anchored in our Code of Ethics, Novartis Ethics, Risk and Compliance (ERC) Program sets clear principles and expectations…\n","protected":false},"author":2,"featured_media":48249,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[127],"tags":[2109,212,2100,2105,2108,206,2104,2099,2103,2107,2106,2101,2102],"class_list":{"0":"post-48248","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-novartis","8":"tag-cell-therapy","9":"tag-gene-therapy","10":"tag-global-healthcare-companies","11":"tag-innovative-healthcare","12":"tag-innovative-medicines","13":"tag-novartis","14":"tag-novartis-oncology-pipeline","15":"tag-novartis-pharmaceuticals","16":"tag-oncology-drug-development","17":"tag-rare-disease-patients","18":"tag-rare-disease-treatment","19":"tag-sandoz","20":"tag-sandoz-pharmaceuticals"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/116400437653846437","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/48248","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=48248"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/48248\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/48249"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=48248"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=48248"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=48248"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}